Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Drynaria quercifolia ethyl acetate fraction is a **plant-derived small-molecule phytochemical extract** prepared from the rhizome of *Drynaria quercifolia*. It has been investigated only in **preclinical academic studies** and does not appear to have a commercial sponsor, approved product name, or established pharmaceutical development program. Reported activities include **antioxidant and anticholinesterase effects** in neurobehavioral models, with amelioration of scopolamine-induced memory impairment in mice, and **antifibrotic/hepatoprotective effects** in experimental liver injury models, where the extract has been associated with modulation of **Nrf2/ARE** and **NFkB** signaling. Because this is a botanical fraction rather than a single chemically defined active ingredient, its pharmacology is best understood as a multi-component phytochemical mixture enriched in phenolics and flavonoids rather than a precisely target-selective drug.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on drynaria quercifolia ethyl acetate fraction.